Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study
International Journal of Clinical Oncology · 2026-08 · 31 (8) · 1597-1606
DOI: 10.1007/s10147-026-03067-2 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 26.05.2026. Verfasst von Yuki Shin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Biomarkers, Tumor, DNA Copy Number Variations. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In HER2-positive advanced or recurrent gastric cancer, tissue-based HER2 assessment has been established; however, the clinical relevance of ERBB2 copy number (CN) measured from plasma cell-free DNA (cfDNA), particularly its longitudinal change during treatment, remains unclear. METHODS: This was a prespecified ancillary correlative analysis of the phase II KSCC-TROX trial (jRCTs071190007; UMIN000036867), evaluating whether changes in cfDNA ERBB2 CN (ΔCN) reflect clinical outcomes. Of the 66 patients included in the TROX trial analysis set, 55 with baseline blood samples comprised Cohort A, and 34 with paired follow-up samples comprised Cohort B. ERBB2 CN was quantified using droplet digital PCR. RESULTS: Baseline ERBB2 CN was associated with tumor HER2 immunohistochemistry score but not with progression-free survival (PFS) or overall survival (OS) when dichotomized at a cut-off of 2.5. In Cohort B, an increase in ERBB2 CN (ΔCN > 0) was significantly associated with shorter PFS compared with ΔCN ≤ 0 (p = 0.008), which was maintained in multivariable analysis (p = 0.001). OS was also significantly shorter in patients with ΔCN > 0 (p = 0.024). CONCLUSIONS: An increase in cfDNA ERBB2 CN during treatment was independently associated with shorter PFS in HER2-positive advanced gastric cancer. Assessment of ERBB2 CN change may provide a useful biomarker for treatment monitoring and prognostic stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Cancer Center, Gifu University Hospital, Gifu, Japan.
- Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
- Medical Oncology, Saga-Ken Medical Centre Koseikan, Saga, Japan.
- Department of Surgery, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
- Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Zitieren
APA
Shin, Y., Makiyama, A., Yamada, T., Kashiwada, T., Hattori, M., Yamaguchi, T., Shindo, Y., Kawazoe, T., Nambara, S., Tsuda, Y., Nakanoko, T., Ando, K., Yoshizumi, T., Sakai, K., Nishio, K., & Oki, E. (2026). Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study. International Journal of Clinical Oncology, 31(8), 1597-1606. https://doi.org/10.1007/s10147-026-03067-2
Vancouver
Shin Y, Makiyama A, Yamada T, Kashiwada T, Hattori M, Yamaguchi T, et al. Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study. International Journal of Clinical Oncology. 2026;31(8):1597-1606. doi:10.1007/s10147-026-03067-2
BibTeX
@article{Shin2026,
author = {Shin, Yuki and Makiyama, Akitaka and Yamada, Teppei and Kashiwada, Tomomi and Hattori, Masashi and Yamaguchi, Toshifumi and Shindo, Yoshiaki and Kawazoe, Tetsuro and Nambara, Sho and Tsuda, Yasuo and Nakanoko, Tomonori and Ando, Koji and Yoshizumi, Tomoharu and Sakai, Kazuko and Nishio, Kazuto and Oki, Eiji},
title = {Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {8},
pages = {1597--1606},
doi = {10.1007/s10147-026-03067-2}
}
EUVIMED